How does startup valuation work?

Startup valuation is the process of putting a price on your company so you and investors can decide how much equity (ownership) changes hands for a given investment. In early-stage startups—especially medtech—valuation is less about precise math and more about risk pricing: investors pay more when key risks (clinical, regulatory, reimbursement, adoption) are reduced.

Two definitions you’ll use constantly:

• Pre-money valuation: the value of the company before new money goes in.
• Post-money valuation: the value after the investment. Post-money = Pre-money + Investment.

Example: If an investor puts in $2M at a $8M pre-money valuation, post-money is $10M. The investor owns $2M / $10M = 20% (before considering option pools and special terms).

What investors are really valuing in medtech

In medtech, valuation is tightly linked to how far you’ve progressed on a few “gates” that reduce uncertainty. A strong team matters, but investors usually pay up for de-risking milestones that make future fundraising and commercialization more predictable.

1) Regulatory pathway clarity (FDA)

Investors want to know which FDA pathway you’re on and whether it’s credible:

• 510(k): you claim substantial equivalence to a predicate device. Often faster/less risky than novel pathways, so it can support higher valuation at the same traction level.
• De Novo: for novel, low-to-moderate risk devices without a predicate. More uncertainty than 510(k), but can create a new device type (and future predicates).
• PMA: for higher-risk devices requiring extensive clinical evidence. Highest cost/time uncertainty; valuation tends to be more milestone-based.

What moves valuation: documented regulatory strategy, pre-sub feedback (when applicable), clear intended use/indications, and a realistic clinical evidence plan.

2) Clinical evidence and study readiness

Clinical traction isn’t just “we talked to doctors.” It’s evidence quality and the ability to generate more:

• Protocol drafted with endpoints that map to claims and adoption
• IRB pathway understood (single site vs multi-site; investigator-initiated vs sponsor)
• Early feasibility data (even small) that supports the mechanism and usability

Investors discount heavily when the clinical plan is vague or endpoints don’t align with what hospitals and payers care about.

3) Reimbursement and economic buyer clarity

In medtech, “who pays?” can dominate valuation. Investors look for:

• CPT codes (billing codes used for physician services) and whether existing codes apply or a new code pathway is needed (which can take time and is uncertain).
• Whether payment is through hospital budgets, payer reimbursement, value-based care programs, or patient self-pay.
• A credible health economic story (cost offsets, length-of-stay reduction, complication reduction, throughput gains).

If you can’t articulate the reimbursement path, you may still raise—but at a lower valuation and with more investor-protective terms.

4) Hospital procurement reality

Hospitals don’t buy like consumers. Procurement, value analysis committees, IT/security reviews (for digital health), and integration requirements can slow adoption. Valuation improves when you can show:

• Named pilot sites with champions and a timeline to purchase
• Implementation plan (training, workflow, integration, support)
• Pricing model aligned to how hospitals budget (capital vs operating expense)

Common valuation methods (and when they actually work)

Founders often ask for “the formula.” In practice, investors triangulate multiple methods and then negotiate based on market conditions and your leverage.

1) Comparable financings (most common)

This is the most practical early-stage method: what similar companies raised at a similar stage, in a similar market, recently. “Similar” in medtech means:

• Same regulatory class/pathway risk (e.g., 510(k) vs PMA)
• Similar evidence maturity (bench, animal, early human, pivotal-ready)
• Similar commercialization complexity (hospital enterprise sale vs outpatient vs consumer)

Because deal data is often private, you approximate via investor conversations, founder networks, and your own pipeline feedback.

2) Milestone-based valuation (medtech-friendly)

Medtech naturally lends itself to “value inflection points.” Investors may price today based on the probability-weighted value of hitting the next milestone (e.g., design freeze, verification/validation, first-in-human, FDA clearance). The more you can convert uncertainty into a dated plan with owners, the more defensible your valuation becomes.

3) Discounted cash flow (DCF) (rare early, more later)

DCF estimates future cash flows and discounts them back to today. It’s sensitive to assumptions and usually not credible pre-revenue in medtech because timelines and adoption curves vary widely. It becomes more relevant once you have repeatable sales and gross margin data.

4) Venture capital method (back-solving from exit)

Some investors back-solve from a potential exit value and their required return. This can be useful to understand investor logic, but it’s not a “truth machine.” In medtech, exit outcomes depend heavily on regulatory success, reimbursement, and strategic buyer interest.

Valuation is not just a number: terms can change the real price

Two deals with the same headline valuation can be very different because of terms (the legal/economic rules of the investment). Key concepts:

• Option pool: shares reserved for future hires. If the pool is created/expanded before the round, it effectively lowers founder ownership (and your “effective” pre-money).
• Liquidation preference: who gets paid first at an exit. A “1x non-participating” preference is common; more aggressive structures can reduce founder outcomes even at high valuations.
• Participating preferred: investors may get their money back and share in remaining proceeds—often worse for founders.
• Pro-rata rights: investor right to maintain ownership in future rounds. Usually reasonable, but can affect future fundraising dynamics.

In plain English: don’t optimize for the biggest valuation if it comes with terms that quietly transfer downside to you and upside to the investor.

Convertible notes and SAFEs: valuation without a valuation (at first)

At pre-seed, medtech founders often raise using a convertible note (debt that converts into equity later) or a SAFE (Simple Agreement for Future Equity). These delay setting a priced valuation until a later round.

Instead, they use:

• Valuation cap: the maximum valuation at which the investment converts (good for investors; can be okay for founders if it matches traction expectations).
• Discount: converts at a discount to the next round price.

Medtech nuance: because timelines can be longer, caps that look “fine” today can become punitive if the next priced round takes longer than expected. Model dilution under multiple timelines.

How dilution works (and why medtech founders feel it more)

Dilution means your ownership percentage decreases when new shares are issued. That’s normal—what matters is whether the company’s value grows faster than dilution.

A simple example:

• You own 100% at formation.
• You raise a round where investors buy 20% post-money.
• After the round, you own 80% (before considering option pool changes).

Medtech often requires more capital to reach clearance, reimbursement, and scaled sales—so founders may go through more rounds. The antidote is not “avoid dilution at all costs,” but to raise to clear the next major risk so the next round is at a meaningfully higher valuation.

What to do next

1. Map your next 1–2 value inflection milestones (e.g., regulatory pathway confirmation, first clinical data, signed pilot with procurement path) and estimate time/cost to reach them.
2. Model dilution scenarios for a SAFE/note vs priced round, including option pool changes and a slower-than-expected timeline. Use /finances.
3. Pressure-test your FDA and evidence plan so your valuation story is anchored in de-risking, not hype. Capture it in a tight narrative using /launchpad.
4. Run a comparable check by interviewing 10–15 founders/investors in adjacent medtech categories and documenting ranges and terms you hear (not just valuations). Use /interviews.